Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $1.79 and traded as low as $1.76. enGene shares last traded at $1.76, with a volume of 1,008,041 shares trading hands.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. Wells Fargo & Company upgraded shares of enGene from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $2.00 to $6.00 in a report on Thursday, November 12th. UBS Group reiterated an “outperform” rating on shares of enGene in a research report on Thursday, November 12th. Jefferies Financial Group raised enGene to a “strong-buy” rating in a report on Tuesday, October 13th. Leerink Partners raised shares of enGene from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Friday, November 13th. Finally, Weiss Ratings raised shares of enGene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.75.
View Our Latest Stock Analysis on ENGN
enGene Stock Down 4.9%
The business has a 50 day moving average of $1.79 and a two-hundred day moving average of $3.81. The stock has a market capitalization of $117.96 million, a PE ratio of -0.85 and a beta of -0.24. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21.
enGene (NASDAQ:ENGN – Get Free Report) last issued its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). Analysts predict that enGene Holdings Inc. will post -1.82 EPS for the current year.
Institutional Trading of enGene
Several institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP acquired a new stake in enGene during the first quarter worth about $251,000. Sei Investments Co. acquired a new position in enGene in the first quarter valued at approximately $409,000. Renaissance Technologies LLC boosted its position in enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after purchasing an additional 135,318 shares in the last quarter. SR One Capital Management LP acquired a new stake in shares of enGene during the 2nd quarter worth approximately $1,293,607. Finally, Monashee Investment Management LLC increased its holdings in shares of enGene by 8.5% during the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after purchasing an additional 25,000 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
See Also
- Five stocks we like better than enGene
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
